— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered in

Encuentre Glaxosmithkline plc: noticias de ADR (GSK), eventos corporativos, comunicados de prensa, últimas actualizaciones de la empresa y titulares

GSK stock is trading in the low $50s as a US FDA approval for Tivicay PD adds fresh support to the H

GSK’s (GSK) shingles vaccine, Shingrix, is linked to a lower risk of major cardiovascular events compared with Merck

Filing details 9.221 notional GSK ADS acquired at $51.78 each by president Maya Martinez-Davis on 24 Aug 2026 within her executive savings plan.

GSK plc (LSE/NYSE: GSK) shares edged lower in early Monday trading, even as the pharmaceutical company announced two significant regulatory developments

Why GSK (LSE:GSK) matters to UK healthcare stocks as London weighs regulatory decisions, procedure demand and a shifting economic backdrop.